Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
2000 1
2006 1
2012 1
2020 3
2021 12
2022 389
2023 590
2024 225

Text availability

Article attribute

Article type

Publication date

Search Results

1,111 results

Results by year

Filters applied: . Clear all
Page 1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
RESULTS: A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). ...Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with n …
RESULTS: A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir gr …
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD, Depcinski S, Sharma M. Saravolatz LD, et al. Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180. Clin Infect Dis. 2023. PMID: 35245942 Free PMC article. Review.
Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunodeficiency virus type 1 protease inhibitor. Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-rito …
Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunod …
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R. Cao Z, et al. N Engl J Med. 2023 Feb 2;388(5):406-417. doi: 10.1056/NEJMoa2208822. Epub 2022 Dec 28. N Engl J Med. 2023. PMID: 36577095 Free PMC article. Clinical Trial.
BACKGROUND: Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). ...The incidence of adverse events was lower in the VV116 group than in the nirmatrelvir-ritonavir group (67.4% vs. 7 …
BACKGROUND: Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2 …
Nirmatrelvir.
[No authors listed] [No authors listed] 2023 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 May 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 35073029 Free Books & Documents. Review.
Nirmatrelvir is given in combination with ritonavir, which enhances its bioavailability. Minimal information is available on the use of nirmatrelvir during breastfeeding. Ritonavir is excreted into milk in measurable concentrations and low levels can be found in the …
Nirmatrelvir is given in combination with ritonavir, which enhances its bioavailability. Minimal information is available on the use …
Nirmatrelvir/ritonavir (Paxlovid).
[No authors listed] [No authors listed] 2022 Jul. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2022 Jul. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 36228054 Free Books & Documents. Review.
This sheet is about exposure to nirmatrelvir/ritonavir in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider....
This sheet is about exposure to nirmatrelvir/ritonavir in pregnancy and while breastfeeding. This information should not take the pla …
Nirmatrelvir/ritonavir (Paxlovid).
[No authors listed] [No authors listed] 2022 Jul. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. 2022 Jul. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. PMID: 36378910 Free Books & Documents. Review.
Esta hoja trata sobre la exposicion a nirmatrelvir/ritonavir en el embarazo y durante la lactancia. Esta informacion no debe usarse como un sustituto de la atencion medica o los consejos de su proveedor de atencion de salud....
Esta hoja trata sobre la exposicion a nirmatrelvir/ritonavir en el embarazo y durante la lactancia. Esta informacion no debe usarse c …
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR, Sheida A, Taghizadieh M, Memar MY, Hamblin MR, Bannazadeh Baghi H, Sadri Nahand J, Asemi Z, Mirzaei H. Hashemian SMR, et al. Biomed Pharmacother. 2023 Jun;162:114367. doi: 10.1016/j.biopha.2023.114367. Epub 2023 Feb 6. Biomed Pharmacother. 2023. PMID: 37018987 Free PMC article. Review.
Nirmatrelvir was combined with another HIV protease inhibitor, ritonavir, to create Paxlovid (Nirmatrelvir/Ritonavir). The metabolizing enzyme cytochrome P450 3 A is inhibited by ritonavir to lengthen the half-life of nirmatrelvir, so rintonavir acts as a pha …
Nirmatrelvir was combined with another HIV protease inhibitor, ritonavir, to create Paxlovid (Nirmatrelvir/Ritonavir). The met …
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Marzolini C, et al. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. Clin Pharmacol Ther. 2022. PMID: 35567754 Free PMC article. Review.
Nirmatrelvir/ritonavir will be primarily administered outside the hospital setting as a 5-day course oral treatment. The ritonavir component boosts plasma concentrations of nirmatrelvir through the potent and rapid inhibition of the key drug-metabolizing enzyme cyto …
Nirmatrelvir/ritonavir will be primarily administered outside the hospital setting as a 5-day course oral treatment. The ritonavir co …
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.
Amani B, Amani B. Amani B, et al. J Med Virol. 2023 Feb;95(2):e28441. doi: 10.1002/jmv.28441. J Med Virol. 2023. PMID: 36576379 Free PMC article. Review.
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for coronavirus disease 2019 (COVID-19). ...
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for coronavirus disease 2019 (COVID-19). ...
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Dryden-Peterson S, et al. Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13. Ann Intern Med. 2023. PMID: 36508742 Free PMC article. Clinical Trial.
The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. ...RESULTS: During the study period, 12 541 (28.1%) patients were prescribed nirmatrelvir plus ritonavir, and 32 010 (71.9%) were not. Patients prescribed nirmatrelvir …
The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. ...RESULTS: During the study period, 12 …
1,111 results